Jacobs Levy Equity Management Inc. Has $1.59 Million Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Jacobs Levy Equity Management Inc. boosted its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 1.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,547,215 shares of the biotechnology company’s stock after acquiring an additional 23,139 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in CytomX Therapeutics were worth $1,594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Miller Financial Services LLC acquired a new stake in shares of CytomX Therapeutics in the 4th quarter valued at $26,000. Traphagen Investment Advisors LLC acquired a new stake in shares of CytomX Therapeutics in the 4th quarter valued at $31,000. Algert Global LLC acquired a new stake in shares of CytomX Therapeutics in the 4th quarter valued at $35,000. Aspire Growth Partners LLC acquired a new stake in shares of CytomX Therapeutics in the 4th quarter valued at $42,000. Finally, Prudential Financial Inc. boosted its stake in shares of CytomX Therapeutics by 76.2% in the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 27,800 shares in the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CTMX shares. Wedbush restated an “outperform” rating and issued a $6.00 target price (up previously from $5.00) on shares of CytomX Therapeutics in a research note on Monday, May 12th. HC Wainwright upgraded shares of CytomX Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Thursday. Piper Sandler lifted their price target on CytomX Therapeutics from $2.50 to $5.00 and gave the company an “overweight” rating in a report on Thursday. Finally, StockNews.com raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday.

CytomX Therapeutics Trading Up 1.5%

Shares of CTMX stock opened at $2.03 on Friday. The business’s 50-day moving average price is $0.82 and its 200-day moving average price is $0.89. CytomX Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $2.55. The firm has a market capitalization of $163.66 million, a price-to-earnings ratio of 11.94 and a beta of 1.11.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The company had revenue of $50.92 million for the quarter, compared to analyst estimates of $35.42 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the previous year, the firm earned $0.17 earnings per share. On average, sell-side analysts predict that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.